John Hoeven sold Bristol-Myers Squibb Company (NYSE: BMY)
John Hoeven (R-ND), a U.S. Senator, has disclosed 2 trades in Bristol-Myers Squibb Company (BMY) since 2016, 1 purchase and 1 sale, worth an estimated $150K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: John Hoeven sold $50,001 - $100,000 of Bristol-Myers Squibb Company (NYSE: BMY) on January 20, 2017. Since that trade, BMY is up +77.86% against the S&P 500 up +272.63%, an outperformance of -194.77%.
Across these filings, John Hoeven has been a balanced trader of BMY (a buy-to-sell ratio of 1.00). Each row in the table below links to that trade and its post-trade performance versus the market.
Data updated
John Hoeven's BMY trades vs the price
BMY is up +77.86% since John Hoeven sold on January 20, 2017, versus +272.63% for the S&P 500.
Performance since this trade
All John Hoeven BMY trades
John Hoeven & BMY trading FAQ
Is it legal for John Hoeven to trade Bristol-Myers Squibb Company (BMY) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Bristol-Myers Squibb Company (BMY), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did John Hoeven sell BMY?
John Hoeven disclosed a sale of $50,001 - $100,000 of Bristol-Myers Squibb Company (BMY) on January 20, 2017, according to public STOCK Act filings.
How has BMY performed since John Hoeven's trade?
Since John Hoeven sold BMY on January 20, 2017, the stock is up +77.86%, versus +272.63% for the S&P 500 over the same period, an outperformance of -194.77%.
How many times has John Hoeven traded BMY?
John Hoeven has disclosed 2 BMY trades since 2016 (1 purchase and 1 sale). Every disclosed trade is listed on this page.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional BMY trades?
Quantellect tracks every disclosed congressional trade in Bristol-Myers Squibb Company (BMY) on the Bristol-Myers Squibb Company congressional trading page, which aggregates filings across all members of Congress.
John Hoeven's BMY tradesAll congressional filings for Bristol-Myers Squibb CompanyJohn Hoeven's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.